NEW YORK — Indivumed and Ultivue said on Wednesday that they have agreed to combine certain of their technologies into an offering for personalized cancer drug development.
Under the terms of the deal, the companies will join Indivumed's collection of standardized tissue biospecimens and immunohistochemistry (IHC) expertise with Ultivue's InSituPlex platform for high-throughput multiplex immunofluorescence.
Additional terms were not disclosed.
"By bringing Ultivue's technology and expertise into our workflow, we're giving our customers access to the contextual profiling of key cellular phenotypes," Indivumed Founder and CEO Hartmut Juhl said in a statement. "The data that can now be extracted from these valuable assets in our repository can support the full characterization of samples for biomarker and target discovery, drug development, clinical trials, and individualized therapy research. It will complete our offer in combination with the existing broad menu of IHC assays and end-to-end service."
In April, Hamburg, Germany-based Indivumed signed an agreement to integrate its IndivuType multiomic cancer database with genome and transcriptome-level data collected for samples collected using Personalis' advanced cancer genomics technology.
In July, Cambridge, Massachusetts-based Ultivue began collaborating with OracleBio on an end-to-end workflow for tissue-based biomarker analysis.